The PennZone

  • Home
  • Business
  • Construction
  • Technology
  • Real Estate
  • Non-profit
  • Travel
  • Health
  • Entertainment

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Ice Melts. Infrastructure Fails. What Happens to Clean Water?
  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • 2026 Pre-Season Testing Confirms a Two-Tier Grid as Energy Management Defines Formula 1's New Era
  • The Philadelphia Party Launches to Expand Civic Leadership, Candidate Pathways, and Education
  • Platinum Car Audio LLC Focuses on Customer-Driven Vehicle Audio and Electronics Solutions
  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • Postmortem Pathology Expands Independent Autopsy Services Across Colorado

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Open House Momentum Builds at Heritage at South Brunswick
  • A Celebration of Visibility, Voice and Excellence: The 57th NAACP Image Awards Golf Invitational, Presented by Wells Fargo, A PGD Global Production
  • TopDogTours Expands Award-Winning Walking Tours in Philadelphia with Immersive Experiences
  • Athens in Spring: A Culinary City Break That Rivals Paris and Copenhagen
  • ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
  • Jayne Williams Joins Century Fasteners Corp. Sales and Business Development Team
  • Lord of the Rings Star Orlando Bloom To Host Special Experience at FAN EXPO Philadelphia
  • Rocket Fibre Services Growing Customer Base With netElastic Networking Software
  • Cummings Graduate Institute for Behavioral Health Studies Honors New Doctor of Behavioral Health Graduates
  • IDpack v4 Launches: A Major Evolution in Cloud-Based ID Card Issuance
  • Corey Lakins Set to Launch Glow Your Influence, a Podcast Spotlighting Women Leaders
  • CCHR Says Psychiatry's Admission on Antidepressant Withdrawal Comes Far Too Late
  • 505 Plumbing, Heating & Cooling Launches in Albuquerque, Bringing a Customer-First Approach to Home Services
  • As AI.com Sells For Record $70 Million, Attention Now Turns To ArtificialIntelligence.com
  • AOW Event Sponsored By The Stanglwirt Resort a renowned five-star Austrian wellness destination
  • Average US gambler spends $210 per month in 2026
  • 10X Recruitment Launches Operator-Led Executive Search for Behavioral Health and Legal Leaders
  • Integris Composites developing armor for military in Arctic Circle
  • Caraline Skincare's Gentle Glow Cleansing Oil Named Finalist for Best Face Cleanser at the 2026 CertClean Clean Beauty Awards​
  • Workplace safety ideas from the front lines to highlight Applied Ergonomics Conference in Arlington, Texas

Popular on PennZone

  • Michael Judkins Releases New Poetry Book, Deeper Than You Think
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Accountants Near Me Cheyenne Opens U.S. Directory for Accountants, Bookkeepers and Tax Services
  • OneVizion Announces Next Phase of Growth as Brad Kitchens Joins Board of Directors
  • Precision Adult Care Expands 24/7 Adult In-Home Care Services to Meet Growing Demand in the Coachella Valley
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Jim Breuer is Coming to The Eichelberger Performing Arts Center This May
  • Roshni Online Services Unveils Plans for Innovative Digital Consultation Platform
  • The Ms. Corporate America Maryland Competition Returns for an Unforgettable Evening of Leadership, Excellence, and Empowerment
  • Luxury Lake-View Home Launches in Kissimmee's Bellalago community, Offering Privacy, Space, and Florida Resort-Style Living

Similar on PennZone

  • Postmortem Pathology Expands Independent Autopsy Services in Kansas City
  • ClearSight Therapeutics Signs LOI with Covalent Medical for $60M Multi-Channel OTC Eye Care Partnership
  • Capsadyn® Launches on Amazon, Offering Non-Burning Capsaicin Pain Relief
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • Parkway Prosthodontics Achieves Breakthrough Full-Arch Reconstruction Case
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • EPP Pricing Platform announces leadership transition to support long-term growth and continuity
  • Stipenda Appoints David Epstein as Chief Operating Officer
  • Metavalis Launches Massive Community Coat Drive in Branson to Support Local Residents
  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us